Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Karolinska Institutet
The Switzerland-headquartered group believes it has a potentially best-in-class GLP-2 agonist on its hands with apraglutide, which has proved effective in a subgroup of patients that do not benefit from standard of care Gattex.
Deal Snapshot: VectivBio is expanding its existing focus on rare diseases into inherited metabolic disorders, which affect about one in 800 live births and cause significant mortality in infants and young people.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
- Academic and Research Institutions
- Other Names / Subsidiaries
- BioArtic Neuroscience AB
- Umecrine Cognition
- Umecrine Company Group
- Umecrine AB